BRilife

Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary

NRx Pharmaceuticals to lead BriLife Vaccine Trial in Caucasus Region NRx Pharmaceuticals with Support from the Israel Institute for Biological Research to lead BriLife Vaccine Development and Commercialization RADNOR, Pa., Aug. 23, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who […]

NRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia

Dose-Confirmatory Trial Follows Successful Phase 2a Trial Preclinical and Early Human Data Indicate BriLife™ May Confer Enhanced Immunity Against Delta variant RADNOR, Pa., Aug. 9, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the BriLife™ vaccine against COVID-19 in the Nation of Georgia.  The vaccine […]